Related Experiment Video
Updated: Jul 12, 2025
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
Molecular docking analysis of MCL-1 inhibitors for breast cancer management
Alzahrani Abdulrahman1, Kamal Mohammad Azhar2, Akber Asif Hussain3
1Department of Applied Medical Sciences, Applied College, Al-Baha University, Al-baha City, Kingdom of Saudi Arabia.
Abstract:
Myeloid leukemia 1 (MCL-1), a BCL-2 protein family member, acts as an anti-apoptotic protein by interacting with pro-apoptotic BCL-2 proteins. Its overexpression is frequently observed in numerous cancer types including breast cancer, and is closely linked to the initiation and progression of tumors as well as poor prognosis and resistance to therapeutic interventions. Here, a database of 3402 chemicals with established therapeutic activity against various diseases was chosen and systematically screened against the MCL-1 protein. Visual inspection and binding energy analysis revealed that the compounds OSU-03012, Raltitrexed, Ostarine (MK-2866), Dovitinib (TKI-258), and Varespladib (LY315920) had strong binding affinity for the MCL-1 protein. Notably, their binding affinity was higher than that of the control compounds. These compounds exhibited strong interactions with critical amino acid residues of the MCL-1 protein. Furthermore, these compounds shared several common amino acid residue interactions with the control compounds. These findings suggest that these compounds may be useful as MCL-1 inhibitors in the treatment of breast cancer. However, additional experimental validation is required to confirm these findings.
Insights
Researchers screened 3402 compounds to identify myeloid leukemia 1 (MCL-1) inhibitors for breast cancer treatment. Five compounds, including OSU-03012 and Raltitrexed, showed strong binding affinity to MCL-1, suggesting potential therapeutic applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Myeloid leukemia 1 (MCL-1) is an anti-apoptotic protein in the BCL-2 family.
- Overexpression of MCL-1 is linked to various cancers, including breast cancer, promoting tumor growth and therapeutic resistance.
Purpose of the Study:
- To identify novel chemical compounds that inhibit MCL-1.
- To evaluate the binding affinity of selected compounds to the MCL-1 protein.
Main Methods:
- Systematic screening of a database containing 3402 chemicals with known therapeutic activities.
- Visual inspection and binding energy analysis to assess compound interactions with MCL-1.
Main Results:
- Five compounds (OSU-03012, Raltitrexed, Ostarine, Dovitinib, Varespladib) demonstrated strong binding affinity to MCL-1.
- These compounds exhibited higher binding affinity than control compounds and interacted with critical MCL-1 amino acid residues.
Conclusions:
- The identified compounds show potential as MCL-1 inhibitors for breast cancer therapy.
- Further experimental validation is necessary to confirm the efficacy and safety of these compounds.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
